Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Nexalin Technology Inc (NXL)

$0.36 -0.02 (-5.00%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	7.43M
Revenue (ttm)	300,000.00
Net Income (ttm)	-8.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,740.00%
Debt to Equity Ratio	0.00

Volume	108,000
Avg Vol	672,338
Day's Range	N/A - N/A
Shares Out	20.58M
Stochastic %K	44%
Beta	4.00
Analysts	Strong Sell
Price Target	$2.00

Company Profile

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic br...

Industry: Medical Devices

Sector: Healthcare

Phone: 832 260 0222

Website: www.nexalin.com

Address:

1776 Yorktown, Suite 550, Houston, United States

MaskMaker Jul. 3 at 10:23 PM

$NXL

0 · Reply

KernelKeltner Jul. 3 at 9:38 PM

$NXL is trying to carve out a niche in neurohealth with its DIFS tech, aiming at mental health and neurological disorders without drugs or side effects. Interesting concept, but it still needs real market validation. Small-cap story with potential if adoption starts to show traction.

0 · Reply

MaskMaker Jul. 2 at 5:25 AM

$NXL

0 · Reply

MarketsParadise Jul. 1 at 8:46 PM

Small caps heating up, We are seeing some big runners lately. Take a look at ticker DRCT 💎 I believe this is the next monster runner waiting to be found: DRCT 💎 • 600K share float--Nano float! • AI-powered digital advertising & marketing drive • Extremely thin chart • Any sustained buying pressure we look for the 5$+. $WXM $NXL $ALDX $RDDT $GH //..

0 · Reply

MaskMaker Jul. 1 at 4:53 PM

$NXL

0 · Reply

MaskMaker Jul. 1 at 1:48 AM

$NXL

0 · Reply

MaskMaker Jun. 30 at 10:08 PM

$NXL I welcome a RS and make this a 500k float. I welcome the scare tactics. I welcome what’s about to come Eventually!

0 · Reply

MaskMaker Jun. 30 at 5:25 PM

$NXL

0 · Reply

Dante_s_Inferno Jun. 30 at 5:45 AM

$NXL 💩

0 · Reply

MaskMaker Jun. 29 at 3:26 PM

$NXL

0 · Reply

Nexalin Technology Proxy statement: Proxy filing

2026-06-23T15:25:14.000Z - 11 days ago

Nexalin Technology investigator wins award for neurostimulation research

Jun 23, 2026, 8:30 AM EDT - 11 days ago

Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS™ Platform

Jun 16, 2026, 9:15 AM EDT - 18 days ago

Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life

2026-06-10T13:32:50.000Z - 24 days ago

Nexalin Technology completes neurostimulation protocol trial

Jun 10, 2026, 9:15 AM EDT - 24 days ago

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

Jun 8, 2026, 6:56 AM EDT - 26 days ago

Nexalin Technology Registration statement

Jun 8, 2026, 6:56 AM EDT - 26 days ago

Nexalin Technology Quarterly report

2026-06-04T14:08:10.000Z - 4 weeks ago

Nexalin Technology announces issuance of new U.S. patent

Jun 4, 2026, 10:00 AM EDT - 4 weeks ago

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

May 21, 2026, 8:30 AM EDT - 6 weeks ago

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

May 19, 2026, 8:30 AM EDT - 6 weeks ago

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

May 8, 2026, 8:00 AM EDT - 2 months ago

Nexalin Technology Quarterly report: Q1 2026

Apr 28, 2026, 9:15 AM EDT - 2 months ago

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

2026-04-22T14:03:36.000Z - 2 months ago

Nexalin Technology enters agreements to advance HALO Clarity trial

Apr 22, 2026, 9:35 AM EDT - 2 months ago

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

2026-04-15T14:21:51.000Z - 2 months ago

Nexalin Technology advances FDA Alzheimer’s strategy

Apr 15, 2026, 10:00 AM EDT - 2 months ago

Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China

Apr 14, 2026, 8:30 AM EDT - 2 months ago

Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21

Apr 9, 2026, 7:47 AM EDT - 3 months ago

Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

2026-04-07T13:31:54.000Z - 3 months ago

Nexalin Technology price target lowered to $2 from $4 at Maxim

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Nexalin Technology Annual report: Q4 2025

Mar 1, 2026, 7:00 AM EST - 4 months ago

Nexalin Technology Slides: Investor presentation

2026-02-24T13:34:50.000Z - 4 months ago

Nexalin announces continued advancement toward trial evaluating HALO Clarity

2026-02-24T13:29:27.000Z - 4 months ago

Nexalin announces continued advancement toward trial evaluating HALO Clarity

Feb 24, 2026, 8:07 AM EST - 4 months ago

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

2026-02-23T13:33:27.000Z - 4 months ago

Nexalin ‘commended’ recent Congressional initiative on neurostim research

Feb 23, 2026, 8:18 AM EST - 4 months ago

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

2026-02-05T13:46:39.000Z - 5 months ago

Nexalin Technology launches AI-designed virtual clinic platform NeuroCare

Feb 5, 2026, 8:37 AM EST - 5 months ago

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care

2026-02-02T13:56:38.000Z - 5 months ago

Nexalin Technology highlights research validating neurostimulation technology

Feb 2, 2026, 8:45 AM EST - 5 months ago

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

2026-01-14T14:05:14.000Z - 6 months ago

Nexalin Technology announces publication of peer-reviewed study on DIFS

Jan 14, 2026, 9:00 AM EST - 6 months ago

Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

2025-12-03T13:05:47.000Z - 7 months ago

Nexalin Technology completes FDA Q-sub meeting for Gen-2 SYNC neurostimulation

Dec 3, 2025, 8:00 AM EST - 7 months ago

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program

Dec 2, 2025, 8:00 AM EST - 7 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4

2025-11-18T14:42:34.000Z - 8 months ago

Nexalin announces results for 15 mA neurostimulation device

Nov 18, 2025, 9:00 AM EST - 8 months ago

Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

Nov 14, 2025, 7:00 AM EST - 8 months ago

Nexalin Technology Quarterly report: Q3 2025

2025-11-13T14:21:40.000Z - 8 months ago

Nexalin Technology appoints Carmi Masha as exclusive distributor in Israel

Nov 13, 2025, 9:15 AM EST - 8 months ago

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

2025-11-05T13:40:36.000Z - 8 months ago

Nexalin Technology announces FDA acceptance of Q-Sub for Gen-2 SYNC

Nov 5, 2025, 8:30 AM EST - 8 months ago

Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia

2025-10-30T12:46:01.000Z - 8 months ago

Nexalin Technology announces regulatory approval to sell Gen 2 SYNC

Oct 30, 2025, 8:30 AM EDT - 8 months ago

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

2025-10-21T13:10:34.000Z - 9 months ago

Nexalin announces three studies published on Gen-2 Nexalin DIFS technology

Oct 21, 2025, 9:00 AM EDT - 9 months ago

Nexalin's DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies

2025-10-13T12:40:42.000Z - 9 months ago

Nexalin Technology appoints Robert Rothstein to Scientific Advisory Board

Oct 13, 2025, 8:30 AM EDT - 9 months ago

Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

Oct 10, 2025, 8:00 AM EDT - 9 months ago

Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit

Oct 8, 2025, 8:30 AM EDT - 9 months ago

Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer's Disease with Gen-2 SYNC Neurostimulation Device

Sep 25, 2025, 8:30 AM EDT - 10 months ago

Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology

Aug 25, 2025, 9:00 AM EDT - 11 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on September 9

Aug 6, 2025, 8:00 AM EDT - 11 months ago

Nexalin Technology Quarterly report: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Proxy statement: Proxy filing

May 28, 2025, 10:00 AM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

May 13, 2025, 8:30 AM EDT - 1 year ago

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

May 13, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Quarterly report: Q1 2025

May 6, 2025, 2:40 PM EDT - 1 year ago

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

May 5, 2025, 8:20 AM EDT - 1 year ago

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

May 1, 2025, 10:30 AM EDT - 1 year ago

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Apr 23, 2025, 9:15 AM EDT - 1 year ago

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Registration statement: Registration filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Apr 14, 2025, 12:30 PM EDT - 1 year ago

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Apr 2, 2025, 8:30 AM EDT - 1 year ago

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Mar 26, 2025, 8:30 AM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Mar 14, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Annual report: Q4 2024

Mar 3, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Feb 28, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Feb 26, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Feb 18, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Feb 10, 2025, 9:00 AM EST - 1 year ago

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Feb 3, 2025, 8:30 AM EST - 1 year ago

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Jan 30, 2025, 7:00 AM EST - 1 year ago

Nexalin Technology Registration statement: Registration filing

Jan 23, 2025, 11:00 AM EST - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Jan 10, 2025, 7:00 AM EST - 1 year ago

Nexalin Technology Registration statement: Registration filing

Dec 23, 2024, 10:00 AM EST - 1 year ago

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

Dec 20, 2024, 7:00 AM EST - 1 year ago

Nexalin Technology Registration statement: Registration filing

Nov 26, 2024, 10:00 AM EST - 1 year ago

New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nov 8, 2024, 7:00 AM EST - 1 year ago

Nexalin Technology Quarterly report: Q3 2024

Nov 1, 2024, 2:00 PM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

MaskMaker Jul. 3 at 10:23 PM

$NXL

0 · Reply

KernelKeltner Jul. 3 at 9:38 PM

0 · Reply

MaskMaker Jul. 2 at 5:25 AM

$NXL

0 · Reply

MarketsParadise Jul. 1 at 8:46 PM

0 · Reply

MaskMaker Jul. 1 at 4:53 PM

$NXL

0 · Reply

MaskMaker Jul. 1 at 1:48 AM

$NXL

0 · Reply

MaskMaker Jun. 30 at 10:08 PM

$NXL I welcome a RS and make this a 500k float. I welcome the scare tactics. I welcome what’s about to come Eventually!

0 · Reply

MaskMaker Jun. 30 at 5:25 PM

$NXL

0 · Reply

Dante_s_Inferno Jun. 30 at 5:45 AM

$NXL 💩

0 · Reply

MaskMaker Jun. 29 at 3:26 PM

$NXL

0 · Reply

PAULSTOCK57 Jun. 29 at 11:08 AM

$NXL another shitty day with NXL Stock ?

1 · Reply

MaskMaker Jun. 28 at 5:48 AM

$NXL

0 · Reply

MaskMaker Jun. 27 at 3:07 PM

$NXL

0 · Reply

MaskMaker Jun. 26 at 11:16 PM

$NXL

0 · Reply

TacticalTrader752 Jun. 25 at 8:49 PM

$SHPH $IPW $IPW $NXL great AH 🔥

0 · Reply

TacticalTrader752 Jun. 25 at 8:25 PM

$NXL wow this is thin. Volume and it doubles

0 · Reply

TacticalTrader752 Jun. 25 at 8:23 PM

$NXL why did this pop?

0 · Reply

MrTicker Jun. 25 at 8:15 PM

$NXL volume picking up.. could see a break above .50

0 · Reply

MaskMaker Jun. 25 at 4:32 AM

$NXL

0 · Reply

Dante_s_Inferno Jun. 24 at 3:19 PM

$NXL when is the deadline for rs?

1 · Reply

MaskMaker Jun. 24 at 5:43 AM

$NXL

0 · Reply

isaacwilliams33 Jun. 23 at 9:13 PM

$NXL has pattern for September/October. Absolute bottom was 18-23cents, 52week low of 30cents. That was the first trade I take with real money actually, If I see itis under 26cents I might pick up a few shares and hold till the Fall.

0 · Reply

1.0.0